Kirti,
Chandan Kumar,
Ritika Saini,
Kashish,
- Assistant Professor, Department of Pharmacy, Adesh Institute of Pharmacy and Biomedical Sciences, Bathinda, Punjab, India
- Assistant Professor, Department of Pharmacy, Amritsar Group of Colleges, Amritsar, Punjab, India
- Assistant Professor, Department of Pharmacy, Amritsar Group of Colleges, Amritsar, Punjab, India
- Research Scholar, Department of Pharmacognosy, Guru Nanak Dev University, Amritsar, Punjab, India
Abstract
Pharmacovigilance is critical in protecting the populace health by monitoring, detecting and preventing adverse drug reaction (ADR) post drug approval. Although there is technological advancement and national initiatives such as the Pharmacovigilance Programme of India (PvPI), there is still a great problem of underreporting. Many benefits of effective pharmacovigilance include identification of risks early, better prescriptions and patient confidence. There are historical examples of drugs being withdrawn due to thalidomide, rofecoxib, and ranitidine, which indicate the significance of post-marketing monitoring during the lifecycle of a drug. Pharmacists play a major role in the detection of ADR and patient counselling and rational drug use. The development of artificial intelligence and big data and patient-centered reporting systems in the future offers a revolutionary breakthrough in the field of safety monitoring. Nevertheless, it is important to fill the knowledge, educational, and infrastructural gaps. Its ability to be the silent watchdog of patient safety will continue to be reinforced by enhancing international cooperation and incorporating patient safety, through pharmacovigilance, into routine healthcare delivery.
Keywords: Pharmacovigilance, Adverse Drug Reactions (ADRs), Patient Safety, Drug Monitoring, Post-Marketing Surveillance, Pharmacovigilance Programme of India (PvPI), Artificial Intelligence, Healthcare Systems.
Kirti, Chandan Kumar, Ritika Saini, Kashish. Pharmacovigilance: The Silent Guardian of Patient Safety. Research and Reviews: A Journal of Pharmacology. 2025; 16(01):-.
Kirti, Chandan Kumar, Ritika Saini, Kashish. Pharmacovigilance: The Silent Guardian of Patient Safety. Research and Reviews: A Journal of Pharmacology. 2025; 16(01):-. Available from: https://journals.stmjournals.com/rrjop/article=2025/view=232354
References
1. Sulashvili N, Jadhav RD, Beglaryan M, Gorgaslidze N, Gabunia L, Alavidze N, et al. THE SCIENTIFIC TALKS OF COMPREHENSIVE ANALYSIS OF PHARMACOGENETIC AND PATIENT-CENTERED CARE APPROACHES ON MEDICATION-INDUCED ADVERSE EFFECTS AND TOXICITIES, PHARMACOVIGILANCE CHALLENGES, IMPLICATED DRUGS, UNDERLYING DETERMINANTS OF RISK, AND STRATEGIC APPROACHES TO PHARMACOTHERAPEUTIC MANAGEMENT. Georgian Scientists. 2025;7(3):217-62.
2. Anestina N, Obiageli C, Anthony O, Alade A, Mustapha A, Oluwaferanmi A. Ensuring Drug Safety: Comprehensive Pharmacovigilance Strategies for Public Health. 2025.
3. Pandian S, Ragavan YV, Pandian AG, Kumaraguru AK, Subramanian KK. Enhancing Public Health with Pharmacovigilance: Tools, Strategies, and Impacts. Biomedical and Pharmacology Journal. 2025;18(2).
4. Religioni U, Barrios-Rodríguez R, Requena P, Borowska M, Ostrowski J. Enhancing therapy adherence: impact on clinical outcomes, healthcare costs, and patient quality of life. Medicina. 2025;61(1):153.
5. Khot A, Dakhale G. Monitoring (Pharmacovigilance). Pharmacovigilance-Facts, Challenges, Limitations and Opportunities: Facts, Challenges, Limitations and Opportunities. 2025:87.
6. Ganhao AM. Experiences of Informal Primary Caregivers of Adult Patients With Aggressive Primary Malignant Brain Tumors: A Qualitative Metasummary: JFK School of Psychology and Social Sciences at National University; 2025.
7. Power L. Understanding Mental Health: The use of narratives by those that have experienced State care. 2025.
8. Rehman W, Arfons LM, Lazarus HM. The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development. Ther Adv Hematol. 2011;2(5):291-308.
9. Doomra R, Inder D, Kumar P. Way forward to pharmacovigilance and adverse drug reaction monitoring in India: A critical review. Journal of Integrative Medicine and Research. 2025;3(2):91-6.
10. McNeilage AG, Browne E, Nielsen S, Ashton‐James CE, Murnion B. Healthcare Practitioner and Other Professionals’ Perspectives on Gabapentinoid Misuse and Dependence: A Systematic Review of Qualitative Studies. European Journal of Pain. 2025;29(9):e70116.
11. Mann NA, Khan ZA, Asghar S, Rani A, Hussain N, Akhtar SS, et al. Patterns of Health Services and Medicine Utilisation by First‐Generation Pakistani Immigrants in New Zealand. Health Expectations. 2025;28(1):e70169.
12. Amekpor F, Mwansa C, Benjamin DO, Adedokun DA, Aderonke TR, Kamfechukwu OG, et al. The Prospects and Challenges of Telemedicine and Digital Health Tools in Enhancing the Timely Reporting and Surveillance of Malaria Cases. Journal of Health Science and Medical Research. 2025:20251167.
13. Skupień ET. The Maturity Model as a Tool for Assessing Transportation Systems on the Example of Inland Navigation. Sustainability. 2025;17(4):1577.
14. Abdel-Basset M, Mohamed R, Chang V. A multi-criteria decision-making framework to evaluate the impact of industry 5.0 technologies: case study, lessons learned, challenges and future directions. Information Systems Frontiers. 2025;27(2):791-821.
15. Ahmed R, TAMIM TR. Enhancing medication safety: the role of community and hospital pharmacists in modern healthcare systems. Radinka Journal of Health Science. 2025;2(3):328-55.
16. Mayimele N. Leadership for Pharmacists: Moving Towards Strategic Roles in the Pharmaceutical Industry: Taylor & Francis; 2025.
Research and Reviews: A Journal of Pharmacology
| Volume | 16 |
| 01 | |
| Received | 05/11/2025 |
| Accepted | 10/11/2025 |
| Published | 15/11/2025 |
| Publication Time | 10 Days |
Login
PlumX Metrics